The abstract is read at the publisher; the summary is JClub's.
Anti-PD-1-based immune checkpoint inhibitor regimens show no clinically important difference in global health-related quality of life versus non-ICI controls, with a pooled 1.78-point LSMD.
- Why it matters: Global HRQoL is a key part of judging immune checkpoint inhibitors, but trial reporting and measurement are inconsistent, limiting clear conclusions about patient-centered benefit.
- What they did: This PRISMA 2020 systematic review and meta-analysis of 82 adult solid-tumor RCTs pooled visit-specific adjusted between-group estimates using random-effects models and MID benchmarks.
- The result: For EORTC QLQ-C30 GHS/QoL, the pooled LSMD was 1.78 (95% CI 0.71–2.86; p=0.002; I2=71.9%), while EQ-5D VAS showed no significant differences and no trial showed clinically meaningful deterioration.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.